Qulipta (Atogepant)
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Preventive treatment of episodic migraine (4–14 migraine days/month) | Adults (≥18 years) | Preventive (daily dosing; 10, 30, or 60 mg) | FDA Approved |
| Preventive treatment of chronic migraine (≥15 headache days/month) | Adults (≥18 years) | Preventive (daily dosing; 60 mg only) | FDA Approved |
Atogepant is the only oral CGRP receptor antagonist approved specifically as a preventive-only migraine therapy with daily dosing, covering both episodic and chronic migraine. It was first approved for episodic migraine prevention in September 2021, and received the chronic migraine indication in April 2023. Unlike rimegepant, which has dual acute-preventive approval, atogepant is indicated solely for prevention. The 2024 American Headache Society position statement identifies CGRP-targeting therapies, including oral gepants, as first-line options for migraine prevention alongside traditional oral preventives, without requiring prior preventive treatment failure.
Acute migraine treatment: Atogepant is not approved for acute treatment. Unlike rimegepant and ubrogepant, atogepant has not been studied in a phase 3 acute treatment trial. Evidence quality: Very low.
Medication overuse headache: The PROGRESS chronic migraine trial allowed enrollment of patients with medication overuse headache. Gepants lack the medication overuse headache risk of triptans and analgesics. Evidence quality: Low.
Dosing
Episodic Migraine Prevention
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Episodic migraine — standard prevention | 10 mg, 30 mg, or 60 mg once daily | Same as starting dose | 60 mg/day | All three doses demonstrated significant efficacy vs placebo; no titration required Can be taken with or without food; no loading dose needed |
| Episodic migraine — with strong CYP3A4 inhibitor | 10 mg once daily | 10 mg once daily | 10 mg/day | Strong CYP3A4 inhibitors increase atogepant AUC 5.5-fold Applies to ketoconazole, itraconazole, clarithromycin, ritonavir |
| Episodic migraine — with OATP inhibitors | 10 mg or 30 mg once daily | 10 mg or 30 mg once daily | 30 mg/day | OATP inhibitors increase atogepant AUC ~2.85-fold Includes cyclosporine, rifampin (single dose as OATP inhibitor) |
| Episodic migraine — severe renal impairment or ESRD | 10 mg once daily | 10 mg once daily | 10 mg/day | CrCl <30 mL/min; for ESRD on dialysis, take after dialysis Renal elimination is a minor route but safety data are limited in this population |
Chronic Migraine Prevention
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Chronic migraine — standard prevention | 60 mg once daily | 60 mg once daily | 60 mg/day | Only the 60 mg dose was studied in chronic migraine (PROGRESS trial) 11% of trial patients used one concurrent oral preventive |
| Chronic migraine — with strong CYP3A4 inhibitor | 10 mg once daily | 10 mg once daily | 10 mg/day | Same dose reduction as episodic migraine for strong inhibitors AUC 5.5-fold increase requires maximum dose reduction |
| Chronic migraine — with strong/moderate CYP3A4 inducer | Not recommended | N/A | N/A | Inducers decrease atogepant exposure (AUC reduced up to 60%); loss of efficacy likely Includes rifampin, phenytoin, carbamazepine, efavirenz |
| Chronic migraine — severe renal impairment or ESRD | Not recommended | N/A | N/A | Insufficient safety data in chronic migraine with severe renal impairment Consider alternative preventive therapy in these patients |
All three approved doses (10, 30, 60 mg) demonstrated statistically significant efficacy over placebo in the ADVANCE trial, with 50% responder rates of 56%, 59%, and 61% respectively (vs 29% placebo). The 60 mg dose showed numerically greater reductions in monthly migraine days but also had higher rates of nausea (9%) and constipation (8%) compared with the 10 mg dose (5% and 6%, respectively). Starting at 10 mg may be reasonable for patients concerned about tolerability, while 60 mg may be preferred when maximal efficacy is desired. No titration is required regardless of starting dose.
Pharmacology
Mechanism of Action
Atogepant is an orally administered small molecule that competitively antagonizes the calcitonin gene-related peptide (CGRP) receptor, blocking CGRP-mediated signaling involved in migraine pathophysiology. Like rimegepant, it targets the receptor (CLR/RAMP1 heterodimer) rather than the CGRP ligand itself. The key distinction of atogepant within the gepant class is its development exclusively as a once-daily preventive agent rather than an acute/dual-purpose treatment. While CGRP receptor antagonism is the shared mechanism among gepants, atogepant has a distinct pharmacokinetic profile from rimegepant and ubrogepant, including a larger volume of distribution and unique transporter substrate properties (OATP1B1/1B3) that create a different drug interaction profile. The daily dosing schedule provides sustained CGRP receptor blockade, reducing the frequency and severity of migraine attacks through continuous modulation of the trigeminovascular pathway.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Tmax ~1–2 h; dose-proportional up to 170 mg/day; food effect not significant (AUC -18%, Cmax -22%); no accumulation | Rapid absorption; can be taken with or without food; no loading dose needed |
| Distribution | Vz/F ~292 L; unbound fraction ~4.7% (~95.3% protein bound) | Large Vd suggests extensive tissue distribution; substrate of P-gp, BCRP, OATP1B1, OATP1B3, and OAT1 transporters |
| Metabolism | Primarily CYP3A4; parent compound and glucuronide metabolite (M23) are the main circulating components | CYP3A4 dependence creates significant interactions with strong inhibitors (5.5-fold AUC increase) and inducers (60% AUC decrease with rifampin) |
| Elimination | t½ ~11 h; CL/F ~19 L/h; 42% unchanged in feces, 5% unchanged in urine | Short half-life supports once-daily dosing with no accumulation; hepatic/fecal elimination predominates over renal |
Side Effects
| Adverse Effect | Incidence (10 / 30 / 60 mg) | Clinical Note |
|---|---|---|
| Nausea | 5% / 6% / 9% (vs 3% placebo) | Most common adverse effect; dose-related; led to discontinuation in 0.6% of patients |
| Constipation | 6% / 6% / 8% (vs 2% placebo) | Dose-related; led to discontinuation in 0.5%; advise adequate hydration and fiber intake |
| Fatigue / Somnolence | 4% / 4% / 5% (vs 4% placebo) | Only marginally above placebo at 60 mg; led to discontinuation in 0.2% |
| Decreased Appetite | 2% / 1% / 3% (vs <1% placebo) | May contribute to weight loss observed with longer-term use |
| Dizziness | 2% / 2% / 3% (vs 2% placebo) | Similar to placebo at lower doses; only marginally higher at 60 mg |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Hypersensitivity (anaphylaxis, dyspnea, rash, urticaria, facial edema) | Rare (postmarketing) | Can occur days after administration | Permanent discontinuation; initiate appropriate therapy; report to manufacturer |
| Hypertension (new-onset or worsening) | Rare (postmarketing) | Most commonly within 7 days of therapy initiation | Monitor BP; consider discontinuation if inadequately controlled |
| Raynaud’s phenomenon (new-onset or worsening) | Rare (postmarketing) | Median 1.5 days after dosing (small molecule CGRP antagonist class data) | Discontinue atogepant; refer for evaluation; most cases resolve after discontinuation |
| Hepatotransaminase elevation (>3× ULN) | 0.9% (vs 1.2% placebo) | During treatment; temporally associated cases noted | Asymptomatic and resolved within 8 weeks of discontinuation; no severe liver injury or jaundice reported |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Nausea | 0.6% | Most common reason for discontinuation across all dose groups |
| Constipation | 0.5% | Generally manageable with dietary measures |
| Fatigue / Somnolence | 0.2% | Rare cause of discontinuation despite being a common side effect |
Atogepant is associated with dose-related decreases in body weight, with 5.3% of patients on 60 mg experiencing a weight loss of at least 7% at any point during trials (vs 2.5% placebo). This may be related to the combined effects of decreased appetite and gastrointestinal adverse effects. While this may be a desirable effect for some patients, unintended weight loss should be monitored, particularly in underweight individuals or those at risk for eating disorders.
Drug Interactions
Atogepant is metabolized primarily by CYP3A4 and is a substrate of multiple transporters including P-gp, BCRP, OATP1B1, OATP1B3, and OAT1. This creates clinically significant interactions with strong CYP3A4 inhibitors and inducers, as well as a unique OATP-mediated interaction not seen with other gepants. Atogepant is not a clinically significant CYP inhibitor or inducer at therapeutic concentrations.
Monitoring
-
Migraine Diary
Continuous; review at 3 months
Routine Track monthly migraine days, headache severity, and acute medication use days. Assess response at 12 weeks as per the ADVANCE and PROGRESS trial endpoints. For patients on strong CYP3A4 inducers, monitor monthly for reduced efficacy. -
Blood Pressure
Baseline, then periodically
Routine Postmarketing reports of new-onset and worsening hypertension with CGRP antagonists, most commonly within 7 days of initiation. Consider discontinuation if BP is inadequately controlled. -
Body Weight
Baseline, then periodically
Routine Weight decrease of at least 7% occurred in up to 5.3% of patients on 60 mg (vs 2.5% placebo). Monitor for unintended weight loss, especially in underweight patients. -
Hepatic Function
Baseline; as clinically indicated
Trigger-based Transaminase elevations >3× ULN occurred in 0.9% of patients (vs 1.2% placebo). Cases temporally associated with treatment resolved within 8 weeks of discontinuation. No severe liver injury reported. -
Drug Interaction Review
At initiation; with any medication change
Routine Atogepant has a complex dose-adjustment table. Check for strong CYP3A4 inhibitors/inducers, OATP inhibitors, and topiramate (weak inducer) co-administration. Dose changes differ between episodic and chronic migraine. -
Raynaud’s Symptoms
Ongoing patient reporting
Trigger-based Median onset ~1.5 days for small molecule CGRP antagonists. Discontinue if new cold-induced color changes or pain in extremities develop.
Contraindications & Cautions
Absolute Contraindications
- Hypersensitivity to atogepant or any component of Qulipta. Reactions have included anaphylaxis and dyspnea, and can occur days after administration.
Relative Contraindications (Specialist Input Recommended)
- Severe hepatic impairment: Total atogepant exposure increased by 38%. Avoid use per FDA labeling due to potential for liver injury.
- Chronic migraine with severe renal impairment or ESRD: Use of atogepant is not recommended in these patients for the chronic migraine indication.
Use with Caution
- Episodic migraine with severe renal impairment or ESRD (CrCl <30 mL/min): Reduce dose to 10 mg once daily. In ESRD on dialysis, preferably take after dialysis session.
- Pre-existing hypertension: Postmarketing reports of new-onset and worsening hypertension. Most common within 7 days of initiation.
- History of Raynaud’s phenomenon: New-onset or worsening symptoms reported; median onset 1.5 days for small molecule CGRP antagonists.
- Pregnancy: Based on animal data, atogepant may cause fetal harm (decreased fetal body weight and skeletal variations in rats; increased visceral and skeletal variations in rabbits). Pregnancy exposure registry available (1-833-277-0206 or empresspregnancyregistry.com).
- Concurrent strong CYP3A4 inhibitors or OATP inhibitors: Requires dose adjustment per Table 1 in prescribing information.
The FDA updated labeling for all CGRP antagonists, including atogepant, to include warnings for hypertension and Raynaud’s phenomenon based on postmarketing reports. For small molecule CGRP antagonists, Raynaud’s symptom onset occurred a median of 1.5 days following dosing. Many cases involved serious outcomes including hospitalization and disability. In most cases, discontinuation of the CGRP antagonist resulted in symptom resolution. Hypertension was most frequently reported within 7 days of therapy initiation, with some cases requiring hospitalization.
Patient Counselling
Purpose of Therapy
Atogepant is a daily preventive medication that reduces the frequency and severity of migraine attacks. It does not treat migraine attacks once they start. Patients should continue to use their prescribed acute migraine treatments (such as triptans or NSAIDs) for breakthrough attacks. Benefit is typically assessed after 12 weeks of consistent daily use. Unlike triptans, atogepant does not carry a risk of medication overuse headache.
How to Take
Take one tablet by mouth once daily, with or without food, at approximately the same time each day. Swallow the tablet whole. If a dose is missed, take it as soon as remembered on the same day, then resume the regular schedule the next day. Do not take two doses in one day to make up for a missed dose. Store at room temperature (20–25°C / 68–77°F).
Sources
- AbbVie Inc. QULIPTA (atogepant) tablets, for oral use: US Prescribing Information. Revised September 2025. FDA Label Primary source for dosing, pharmacokinetics, adverse reactions, drug interactions, dose adjustments, and September 2025 labeling updates.
- Ailani J, Lipton RB, Goadsby PJ, et al. Atogepant for the preventive treatment of migraine (ADVANCE). N Engl J Med. 2021;385(8):695–706. doi:10.1056/NEJMoa2035908 Pivotal phase 3 trial (Study 1) in episodic migraine (N=910) demonstrating significant MMD reduction at all three doses (10, 30, 60 mg) vs placebo.
- Lipton RB, Pozo-Rosich P, Blumenfeld AM, et al. Effect of atogepant for preventive migraine treatment on patient-reported outcomes in the ADVANCE trial. Neurology. 2023;100(8):e764–e777. doi:10.1212/WNL.0000000000201568 Patient-reported outcome analysis from ADVANCE showing significant improvements in migraine-related disability and quality of life measures.
- Pozo-Rosich P, Ailani J, Engstrom E, et al. Atogepant for the preventive treatment of chronic migraine (PROGRESS). Lancet. 2023;402(10404):775–785. doi:10.1016/S0140-6736(23)01049-8 Pivotal phase 3 trial (Study 3) establishing efficacy of atogepant 60 mg QD for chronic migraine prevention (N=778 randomized across three arms; FDA approved the 60 mg QD dose).
- Ashina M, Tepper SJ, Reuter U, et al. Once-daily oral atogepant for the long-term preventive treatment of migraine: findings from a multicenter, randomized, open-label, phase 3 trial. Headache. 2023;63(1):79–88. doi:10.1111/head.14439 52-week open-label extension demonstrating sustained efficacy and long-term safety of daily atogepant in 744 patients.
- Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache. 2024;64(4):333–341. doi:10.1111/head.14692 2024 AHS position statement upgrading CGRP-targeting therapies to first-line preventive status alongside traditional oral preventives.
- Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies — successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338–350. doi:10.1038/s41582-018-0003-1 Comprehensive review of CGRP pathway pharmacology and the development of small molecule receptor antagonists (gepants).
- Russo AF. Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu Rev Pharmacol Toxicol. 2015;55:533–552. doi:10.1146/annurev-pharmtox-010814-124701 Foundational review of the CGRP signaling pathway and its role as a therapeutic target in migraine.
- Deeks ED. Atogepant: first approval. Drugs. 2022;82(1):65–70. doi:10.1007/s40265-021-01661-w Concise first-approval review covering atogepant pharmacology, clinical trial results, and place in therapy.
- Boinpally R, Jakate A, Butler M, Borbridge L, Periclou A. Single-dose pharmacokinetics and safety of atogepant in adults with hepatic impairment: results from an open-label, phase 1 trial. Clin Pharmacol Drug Dev. 2021;10(7):726–733. doi:10.1002/cpdd.916 Phase 1 hepatic impairment PK study establishing the 15–38% AUC increases across impairment severity grades with atogepant 60 mg.
- Boinpally R, Trugman JM, Engstrom E, et al. Pharmacokinetics of atogepant in subjects with renal impairment. Headache. 2023;63(3):399–408. doi:10.1111/head.14474 Renal impairment PK study supporting dose adjustment recommendations for severe renal impairment and ESRD.
- Goadsby PJ, Dodick DW, Ailani J, et al. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial (Study 2). Lancet Neurol. 2020;19(9):727–737. doi:10.1016/S1474-4422(20)30234-9 Phase 2b/3 episodic migraine trial (Study 2 in PI, N=652) providing supporting efficacy data across all three dose levels.